Ironwood Pharmaceuticals | IRWD - Cash And Equivalent


Ironwood Pharmaceuticals reported $220.47M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Almirall EUR 337.77M 14.83M Dec/2025
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
Ardelyx USD 31.21M 36.79M Mar/2026
Astellas Pharma JPY 281.6B 93.23B Mar/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
Charles River Laboratories USD 192.02M 195K Jun/2026
Coherus Biosciences USD 82.92M 32.32M Jun/2026
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Lexicon Pharmaceuticals USD 38.09M 3.76M Mar/2026
MacroGenics USD 66.52M 9.3M Mar/2026
Moderna USD 1.72B 185M Jun/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025